Incyte Corporation announced that the U.S. Food and Drug Administration approved Jakafi XR, an extended‑release formulation of its flagship drug ruxolitinib, for adults with intermediate‑ or high‑risk myelofibrosis, for polycythemia vera patients who are intolerant of hydroxyurea, and for steroid‑refractory acute graft‑versus‑host disease. The approval, granted on May 01 2026, introduces a once‑daily dosing option that could improve patient adherence and retention.
The new formulation is a strategic response to the 2028 patent cliff for the original Jakafi product. By offering an extended‑release version, Incyte aims to extend the commercial life of its core revenue driver while maintaining market share in the growing myeloproliferative neoplasm and graft‑versus‑host disease markets. The global myelofibrosis treatment market is projected to rise from roughly $1.2 billion in 2025 to $2.75 billion by 2032, and the polycythemia vera market is expected to grow from $1.70 billion in 2024 to $3.56 billion by 2032.
Incyte’s recent financial performance underscores the significance of the approval. In the first quarter of 2026, total revenue reached $1.27 billion, up 21% year‑over‑year, with net sales of $1.10 billion, a 20% increase. Jakafi net sales grew 7% to $758 million, reflecting steady demand for the core product. The company’s full‑year 2026 guidance for total net product revenue is $4.77 billion to $4.94 billion, a range that signals confidence in continued growth.
The approval follows a prior setback in March 2023, when the FDA issued a Complete Response Letter for an earlier extended‑release formulation. Incyte addressed the FDA’s concerns—primarily around bioequivalence and additional data requirements—leading to the successful approval in May 2026.
Bill Meury, Incyte’s CEO, said the approval “reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms and GVHD. Jakafi XR offers patients and physicians a once‑daily option, expanding choice without changing the well‑established role of Jakafi in clinical practice.”
Analysts noted that the approval is a key tailwind for Incyte’s pipeline strategy, which also includes Opzelura and other investigational products. The company’s stock has performed strongly, with a 54% return over the past year, and analysts have raised earnings estimates for the upcoming period.
The FDA approval of Jakafi XR is therefore a material event that expands Incyte’s product portfolio, strengthens its financial outlook, and positions the company to mitigate the impact of the 2028 patent cliff.
revised_sentiment_rating
sentiment_rating
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.